GROVESTREET

Thesis

GroveStreet, founded in 1998, is a private equity and venture capital firm that provides institutional investors with customized access to niche segments of the private equity market. The firm focuses on building bespoke portfolios by leveraging its deep network and customer-centric approach to address the complexities of accessing, evaluating, and monitoring top-tier, oversubscribed lower mid-market buyout and venture capital teams. Their investment strategy emphasizes creating fundamental enterprise value through diversification across strategies, sectors (life science, healthcare, technology), time, and geographies, while maintaining manager quality. They invest in venture capital, growth equity, and lower mid-market buyouts, including smaller buyouts, fully subscribed venture funds, and technology private equity from early-stage venture through growth capital, tech buyouts, and restructuring. GroveStreet operates across the United States, Europe, and Asia. As of May 2026, the firm manages over $10 billion in commitments from 14 global investors across more than 45 separate accounts, with another report indicating over $6 billion currently under management. They are known for backing first-time buyout and venture teams and acting as discretionary managers of customized private equity fund-of-funds. Specific check sizes per investment are not disclosed.

Related lists

• Series C+ Healthcare investors